Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity

Cancer Science

Volumn 101, Issue 4, 2010, Pages 1029-1037

  Hsu, Dennis Shin Shian ^a,b   Chang, Shyue Yih ^a,c,d   Liu, Chung Ji ^e   Tzeng, Cheng Hwai ^a,d   Wu, Kou Juey ^a,d   Kao, Jung Yie ^b   Yang, Muh Hwa ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c Department of Otolaryngology ^*  (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NIBRIN; PROTEIN KINASE B; HIGH MOBILITY GROUP N PROTEIN; NSBP1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; FEASIBILITY STUDY; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; VALIDATION STUDY;

CARCINOMA, SQUAMOUS CELL; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HMGN PROTEINS; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957287028     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01471.x     Document Type: Article

References (46)

1. Bettendorf O, Piffko J, Bankfalvi A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 2004; 40: 110-9.
2. Nagler RM. Molecular aspects of oral cancer. Anticancer Res 2002; 22: 2977-80.
3. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995; 24: 450-3.
4. Chen CL, Chi CW, Liu TY. Hydroxyl radical formation and oxidative DNA damage induced by areca quid in vivo. J Toxicol Environ Health A 2002; 65: 327-36.
5. Chen PC, Kuo C, Pan CC, Chou MY. Risk of oral cancer associated with human papillomavirus infection, betel quid chewing, and cigarette smoking in Taiwan - an integrated molecular and epidemiological study of 58 cases. J Oral Pathol Med 2002; 31: 317-22.
6. Department of Health, the Executive Yuan. Cancer Registry Annual Report In Taiwan Area. ROC: Department of Health, Executive Yuan, Taipei, 2006.
7. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax 2003; 58: 435-43.
8. Bosetti C, Garavello W, Gallus S, La Vecchia C. Smoking cessation and the risk of oesophageal cancer: an overview of published studies. Oral Oncol 2006; 42: 866-72.
9. Hsu YB, Chang SY, Lan MC, Huang JL, Tai SK, Chu PY. Second primary malignancies in squamous cell carcinomas of the tongue and larynx: an analysis of incidence, pattern, and outcome. J Chin Med Assoc 2008; 71: 86-91.
10. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
11. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8.
12. Licitra L, Grandi C, Guzzo M et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003; 21: 327-33.
13. Guntinas-Lichius O, Wendt T, Buentzel J et al. A head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol 2009; doi.
14. Chen PH, Ko YC, Yang YH et al. Important prognostic factors of long-term oropharyngeal carcinoma survivors in Taiwan. Oral Oncol 2004; 40: 847-55.
15. Freije J, Kumar JV. Prevention of cancers of oral cavity and pharynx in New York State. N Y State Dent J 2001; 67: 26-30.
16. Tankere F, Camproux A, Barry B, Guedon C, Depondt J, Gehanno P. Prognostic value of lymph node involvement in oral cancers: a study of 137 cases. Laryngoscope 2000; 110: 2061-5.
17. Lydiatt WM, Shah JP, Hoffman HT. American Joint Committee on Cancer. AJCC stage groupings for head and neck cancer: should we look at alternatives? A report of the Head and Neck Sites Task Force. Head Neck 2001; 23: 607-12.
18. Fortin A, Guerry M, Guerry R et al. Chromosome 11q13 gene amplifications in oral and oropharyngeal carcinomas: no correlation with subclinical lymph node invasion and disease recurrence. Clin Cancer Res 1997; 3: 1609-14.
19. Bova RJ, Quinn DI, Nankervis JS et al. Sutherland. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999; 5: 2810-9.
20. Ahomadegbe JC, Barrois M, Fogel S et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 1217-27.
21. Piffkò J, Bànkfalvi A, Tory K et al. Molecular assessment of p53 abnormalities at the invasive front of oral squamous cell carcinomas. Head Neck 1998; 20: 8-15.
22. Petrini JHJ. The Mre11 complex and ATM: collaborating to navigate S phase. Curr Opin Cell Biol 2000; 12: 293-6.
23. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000; 10: 144-50.
24. D'Amours D, Jackson SP. The Mre11 complex: at the crossroads of DNA repair and checkpoint signaling. Nat Rev Mol Cell Biol 2002; 3: 317-27.
25. Lim DS, Kim ST, Xu B et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 2000; 404: 613-7.
26. Zhao S, Weng YC, Yuan SS et al. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature 2000; 405: 474-7.
27. Wu X, Ranganathan V, Weisman DS et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000; 405: 477-82.
28. Stumm M, von Ruskowsky A, Siebert R et al. No evidence for deletions of the NBS1 gene in lymphomas. Cancer Genet Cytogenet 2001; 26: 60-2.
29. Varon R, Reis A, Henze G et al. Mutations in the Nijmegen Breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res 2001; 61: 3570-2.
30. Plisiecka-Halasa J, Dansonka-Mieskowska A, Rembiszewska A, Bidzinski M, Steffen J, Kupryjanczyk J. Nijmegen breakage gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumors. Ann Hum Genet 2002; 66: 353-9.
31. Wilda M, Demuth I, Concannon P, Sperling K, Hameister H. Expression pattern of the Nijmegen breakage syndrome gene, Nbs1, during murine development. Hum Mol Genet 2000; 9: 1739-44.
32. Chiang YC, Teng SC, Su YN, Hsieh FJ, Wu KJ. c-MYC directly regulates the transcription of NBS1 gene involved in DNA double-strand break repair. J Biol Chem 2003; 278: 19286-91.
33. Chen YC, Su YN, Chou PC et al. Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005; 280: 32505-11.
34. Chen YC, Chiang HY, Yang MH et al. Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif. J Mol Med 2008; 86: 401-12.
35. Yang MH, Chiang WC, Chou TY et al. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res 2006; 12: 507-15.
36. Yang MH, Chang SY, Chiou SH et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 2007; 26: 1459-67.
37. T method. Methods 2001; 25: 402-8.
38. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
39. Ehlers JP, Harbour JW. NBS1 expression as a prognostic marker in uveal melanoma. Clin Cancer Res 2005; 11: 1849-53.
40. Labuhn M, Vuaroqueaux V, Fina F et al. Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers 2006; 21: 30-9.
41. Bavi P, Abubaker J, Hussain A et al. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008; 39: 885-94.
42. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
43. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84: 5034-7.
44. Zhou X, Tan M, Stone Hawthorne V et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004; 10: 6779-88.
45. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983-5.
46. Lim J, Kim JH, Paeng JY et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005; 58: 1199-205.